RESEARKA

The current evidence supports submitting a cautious Researka alpha memo: senolytic ABT-263 may backfire in advanced plaques by coupling plaque-cell reduction with EndoMT and mortality risk. The conclusion should be published only as a bounded frontier signal with explicit single-source and preclinical caveats, not as settled evidence against senolytic therapy.

Citation Support

• source_1 Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
• source_2 Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts
• source_3 Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular Senescence
• source_4 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice